RBC Capital Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

RBC Capital analyst Brian Abrahams initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Outperform rating and announces Price Target of $40.